"Leiomyoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.
Descriptor ID |
D007889
|
MeSH Number(s) |
C04.557.450.590.450
|
Concept/Terms |
Leiomyoma- Leiomyoma
- Leiomyomas
- Fibroid Tumor
- Fibroid Tumors
- Tumor, Fibroid
- Tumors, Fibroid
- Fibromyoma
- Fibromyomas
- Fibroid
- Fibroids
Fibroid Uterus- Fibroid Uterus
- Uterus, Fibroid
- Fibroma, Uterine
- Fibromas, Uterine
- Uterine Fibroma
- Uterine Fibromas
- Fibroids, Uterine
- Fibroid, Uterine
- Uterine Fibroid
- Uterine Fibroids
- Leiomyoma, Uterine
|
Below are MeSH descriptors whose meaning is more general than "Leiomyoma".
Below are MeSH descriptors whose meaning is more specific than "Leiomyoma".
This graph shows the total number of publications written about "Leiomyoma" by people in this website by year, and whether "Leiomyoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
1997 | 0 | 1 | 1 |
2000 | 1 | 0 | 1 |
2001 | 1 | 0 | 1 |
2002 | 1 | 0 | 1 |
2003 | 2 | 0 | 2 |
2004 | 3 | 0 | 3 |
2005 | 2 | 1 | 3 |
2006 | 6 | 0 | 6 |
2007 | 1 | 0 | 1 |
2008 | 3 | 0 | 3 |
2009 | 3 | 1 | 4 |
2010 | 2 | 0 | 2 |
2011 | 6 | 0 | 6 |
2012 | 2 | 1 | 3 |
2013 | 6 | 0 | 6 |
2014 | 7 | 1 | 8 |
2015 | 7 | 0 | 7 |
2016 | 11 | 2 | 13 |
2017 | 10 | 3 | 13 |
2018 | 14 | 1 | 15 |
2019 | 4 | 0 | 4 |
2020 | 16 | 2 | 18 |
2021 | 5 | 0 | 5 |
2022 | 13 | 0 | 13 |
2023 | 21 | 0 | 21 |
2024 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leiomyoma" by people in Profiles.
-
Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases-Focus on Epigenetic Mechanisms. Nutrients. 2024 Feb 17; 16(4).
-
Uterine Fibroid Prevalence in a Predominantly Black, Chicago-Based Cohort. Int J Environ Res Public Health. 2024 Feb 14; 21(2).
-
Fibroids and unexplained infertility treatment with epigallocatechin gallate: a natural compound in green tea (FRIEND) - protocol for a randomised placebo-controlled US multicentre clinical trial of EGCG to improve fertility in women with uterine fibroids. BMJ Open. 2024 01 12; 14(1):e078989.
-
Bromodomain-Containing Protein 9 Regulates Signaling Pathways and Reprograms the Epigenome in Immortalized Human Uterine Fibroid Cells. Int J Mol Sci. 2024 Jan 11; 25(2).
-
Survivin-Sodium Iodide Symporter Reporter as a Non-Invasive Diagnostic Marker to Differentiate Uterine Leiomyosarcoma from Leiomyoma. Cells. 2023 12 13; 12(24).
-
Evidence-Based Approach for Secondary Prevention of Uterine Fibroids (The ESCAPE Approach). Int J Mol Sci. 2023 Nov 04; 24(21).
-
Current and Emerging Treatment Options for Uterine Fibroids. Drugs. 2023 Dec; 83(18):1649-1675.
-
Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study. Am J Obstet Gynecol. 2024 Feb; 230(2):237.e1-237.e11.
-
Fibroids and Fertility. Obstet Gynecol Clin North Am. 2023 Dec; 50(4):663-675.
-
Endocrine-disrupting chemicals and epigenetic reprogramming in developmental origin of uterine fibroids. Sci Prog. 2023 Oct-Dec; 106(4):368504231215601.